WallStreetZenWallStreetZen

NASDAQ: IRLA
Irulya Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for IRLA

Based on 6 analysts offering 12 month price targets for Irulya Therapeutics Inc

Min Forecast
$70.00+111.61%
Avg Forecast
$75.17+127.23%
Max Forecast
$82.00+147.88%

Should I buy or sell IRLA stock?

Based on 6 analysts offering ratings for Irulya Therapeutics Inc.

Strong Buy
Strong Buy
2 analysts 33.33%
Buy
4 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although IRLA's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates IRLA as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their IRLA stock forecasts and price targets.

IRLA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-10-09
lockedlocked$00.00+00.00%2026-09-24
lockedlocked$00.00+00.00%2026-09-22
lockedlocked$00.00+00.00%2026-08-18
lockedlocked$00.00+00.00%2026-07-29
Leerink Partners
Top 29%
72
BuyInitiates Coverage On$80.00+141.84%2026-06-24

1 of 1

Forecast return on equity

Is IRLA forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is IRLA forecast to generate an efficient return on assets?

Company
-4.36%
Industry
23.35%
IRLA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IRLA earnings per share forecast

What is IRLA's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$7.79
Avg 2 year Forecast
-$5.94
Avg 3 year Forecast
-$6.31

IRLA revenue forecast

What is IRLA's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

IRLA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IRLA$33.08$75.17+127.23%Strong Buy
EYPT$0.41$18.57+4,485.43%Buy
CRVO$2.31$21.50+830.74%Strong Buy
LITS$1.16N/AN/A
CELU$0.98N/AN/A
View Top Biotech Stocks

Irulya Therapeutics Stock Forecast FAQ

Is Irulya Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: IRLA) stock is to Strong Buy IRLA stock.

Out of 6 analysts, 2 (33.33%) are recommending IRLA as a Strong Buy, 4 (66.67%) are recommending IRLA as a Buy, 0 (0%) are recommending IRLA as a Hold, 0 (0%) are recommending IRLA as a Sell, and 0 (0%) are recommending IRLA as a Strong Sell.

If you're new to stock investing, here's how to buy Irulya Therapeutics stock.

What is IRLA's earnings growth forecast for 2026-2028?

(NASDAQ: IRLA) Irulya Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.47%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.74%.

Irulya Therapeutics's earnings in 2026 is -$92,476,000.On average, 9 Wall Street analysts forecast IRLA's earnings for 2026 to be -$7,921,599, with the lowest IRLA earnings forecast at -$8,751,217, and the highest IRLA earnings forecast at -$6,076,443. On average, 9 Wall Street analysts forecast IRLA's earnings for 2027 to be -$6,037,998, with the lowest IRLA earnings forecast at -$13,276,334, and the highest IRLA earnings forecast at -$3,727,027.

In 2028, IRLA is forecast to generate -$6,420,108 in earnings, with the lowest earnings forecast at -$13,984,006 and the highest earnings forecast at -$3,897,894.

What is IRLA's revenue growth forecast for 2026-2028?

(NASDAQ: IRLA) Irulya Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.16%.

Irulya Therapeutics's revenue in 2026 is $0.On average, 8 Wall Street analysts forecast IRLA's revenue for 2026 to be $0, with the lowest IRLA revenue forecast at $0, and the highest IRLA revenue forecast at $0. On average, 8 Wall Street analysts forecast IRLA's revenue for 2027 to be $0, with the lowest IRLA revenue forecast at $0, and the highest IRLA revenue forecast at $0.

In 2028, IRLA is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is IRLA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: IRLA) forecast ROA is -4.36%, which is lower than the forecast US Biotechnology industry average of 23.35%.

What is IRLA's Price Target?

According to 6 Wall Street analysts that have issued a 1 year IRLA price target, the average IRLA price target is $75.17, with the highest IRLA stock price forecast at $82.00 and the lowest IRLA stock price forecast at $70.00.

On average, Wall Street analysts predict that Irulya Therapeutics's share price could reach $75.17 by Oct 9, 2027. The average Irulya Therapeutics stock price prediction forecasts a potential upside of 127.23% from the current IRLA share price of $33.08.

What is IRLA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: IRLA) Irulya Therapeutics's current Earnings Per Share (EPS) is -$142.31. On average, analysts forecast that IRLA's EPS will be -$7.79 for 2026, with the lowest EPS forecast at -$8.60, and the highest EPS forecast at -$5.97. On average, analysts forecast that IRLA's EPS will be -$5.94 for 2027, with the lowest EPS forecast at -$13.05, and the highest EPS forecast at -$3.66. In 2028, IRLA's EPS is forecast to hit -$6.31 (min: -$13.75, max: -$3.83).

What is IRLA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: IRLA) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.